| 产品描述： | BMS-P5 is a specific and orally active peptidylarginine deiminase 4 (PAD4) inhibitor. BMS-P5 blocks MM-induced NET formation and delays progression of MM in a syngeneic mouse model |
| 靶点： |
PAD |
| 体外研究： |
BMS-P5 blocks calcium ionophore-induced citrullination of histone H3. BMS-P5 is also able to inhibit formation of NETs induced by primary MM cells isolated from the BM of patients with MM. Cell Viability Assay Cell Line: Neutrophils. Concentration: 10 µM and 100 µM. Incubation Time: 30 min followed by addition of DP42 or 5TGM1 CM. Result: Prevented MM-induced NET formation. |
| 体内研究： |
BMS-P5 (50 mg/kg, oral gavage) significantly improves survival of MM-bearing mice. BMS-P5 (50 mg/kg, oral gavage) may attenuate the presence of pro-tumorigenic proteins in the tumor microenvironment, and thus delay tumor progression. Animal Model: Syngeneic mouse model of MM. Dosage: 50 mg/kg. Administration: Oral gavage, twice a day beginning on day 3 after tumor cell injection. Result: Significantly delayed development of symptoms and significantly prolonged survival of MM-bearing mice. |
| 参考文献： |
1. Marina Li, et al. A Novel Peptidylarginine Deiminase 4 (PAD4) Inhibitor BMS-P5 Blocks Formation of Neutrophil Extracellular Traps and Delays Progression of Multiple Myeloma. Mol Cancer Ther. 2020 Jul;19(7):1530-1538. |
| 溶解性： |
Soluble in DMSO |
| 保存条件： |
-20℃ |
| 配置溶液浓度参考： |
|
1mg |
5mg |
10mg |
| 1 mM |
1.964 ml |
9.822 ml |
19.644 ml |
| 5 mM |
0.393 ml |
1.964 ml |
3.929 ml |
| 10 mM |
0.196 ml |
0.982 ml |
1.964 ml |
| 50 mM |
0.039 ml |
0.196 ml |
0.393 ml |
|
| 注意： |
部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京